Quanterix (Quanterix) LT-Debt-to-Total-Asset : 0.09 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Quanterix LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Quanterix's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.09.

Quanterix's long-term debt to total assets ratio declined from Dec. 2022 (0.10) to Dec. 2023 (0.09). It may suggest that Quanterix is progressively becoming less dependent on debt to grow their business.

Quanterix LT-Debt-to-Total-Asset Historical Data

The historical data trend for Quanterix's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quanterix LT-Debt-to-Total-Asset Chart

Quanterix Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.08

0.04

0.10

0.09

Quanterix Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.10	0.10	0.09	0.09	0.09

Quanterix LT-Debt-to-Total-Asset Calculation

Quanterix's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	37.223	/	425.011
	=	0.09

Quanterix's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	37.223	/	425.011
	=	0.09

Quanterix (NAS:QTRX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Quanterix LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Quanterix's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Quanterix (Quanterix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quanterix Corp (NAS:QTRX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Middlesex Turnpike, Billerica, MA, USA, 01821

Website

https://www.quanterix.com

Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum and other fluids which are undetectable using conventional, analog immunoassay technologies. The company has developed Simoa technology which is a method of detection of proteins and has the capability of analyzing nearly six biomarkers per test, with anticipated expansion capability.

Executives

Laurie J Olson	director	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
William P Donnelly	director	C/O INGERSOLL RAND INC., 525 HARBOUR PLACE DRIVE, SUITE 600, DAVIDSON NC 28036
Vandana Sriram	officer: Chief Financial Officer	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Brian J Blaser	director	561 CIRCLE LANE, LAKE FOREST IL 60045
Michael A Doyle	officer: CFO and Treasurer	C/O EASYLINK SERVICES CORPORATION, 33 KNIGHTSBRIDGE ROAD, PISCATAWAY NJ 08854
Masoud Toloue	officer: President, Quanterix & Dx	C/O QUANTERIX CORP, 900 MIDDLESEX TURNPIKE, BILLERICA MA 01821
Sarah E. Hlavinka	director	2111 N MOLTER RD, LIBERTY LAKE WA 99019
Paul M Meister	director	18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862
David R Walt	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Martin D Madaus	director	290 CONCORD ROAD, BILLERICA MA 01821
John J Fry	officer: General Counsel & Secretary	8 CENTENNIAL DRIVE, PEABODY MA 01960
E Kevin Hrusovsky	director, officer: EC, President & CEO	68 ELM STREET, HOPKINTON MA 01748
Karen Flynn	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
David C. Duffy	officer: SVP R&D and CTO	C/O QUANTERIX CORPORATION, 113 HARTWELL AVENUELE, LEXINGTON MA 02421
Dawn Mattoon	officer: Sr VP, Stgc Mrktg & Assay Tech	113 HARTWELL AVENUE, C/O QUANTERIX CORPORATION, LEXINGTON MA 02421